LRRC8E Activators
LRRC8E-containing volume-regulated anion channels (VRACs) encompass a variety of compounds that can modulate the activity of these channels through different mechanisms. DCPIB, a potent inhibitor of VRACs, can selectively activate LRRC8E-containing channels by inhibiting other VRAC complexes that do not include LRRC8E. Indanyloxyacetic acid (IAA-94), another chloride channel blocker, operates on a similar principle. It may preferentially inhibit non-LRRC8E VRACs, thereby indirectly increasing the activity of channels that incorporate LRRC8E. Phloretin and benzbromarone can also activate LRRC8E by potentially interacting with the membrane environment or directly with the channel itself, leading to altered gating properties. Similarly, flufenamic and niflumic acids, both of which belong to the fenamate group of NSAIDs, can interact with various ion channels, including LRRC8E-containing VRACs, possibly affecting membrane dynamics or directly modulating channel function.
Tamoxifen, known primarily for its actions as a selective estrogen receptor modulator, can induce activation of LRRC8E-containing channels by altering cellular signaling pathways that affect channel regulation. Benzbromarone, through its action on renal anion transport, may also serve as an activator by direct or indirect mechanisms. DIDS, by inhibiting other anion channels, can upregulate LRRC8E-containing VRAC activity as the cell compensates to maintain ion homeostasis. Clofibric acid's interaction with the lipid membrane or regulatory proteins may lead to the activation of LRRC8E. Taurine, which plays a role in cell volume regulation, can activate LRRC8E as part of the cellular response to osmotic stress. Finally, arachidonic acid, a fatty acid involved in cell signaling, can modulate the activity of LRRC8E-containing channels, likely by altering the lipid environment of the membrane or activating signaling pathways that lead to channel opening. Each of these activators, through distinct interactions and modulations, can influence the function of LRRC8E-containing anion channels.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
DCPIB is known as a potent and selective inhibitor of volume-regulated anion channels (VRACs). LRRC8E forms part of the VRAC complex, and their activity is typically inhibited by DCPIB. However, in a scenario where LRRC8E is part of a heteromeric assembly that is not sensitive to DCPIB, the presence of this compound could lead to the selective activation of LRRC8E-containing VRACs by inhibiting other VRACs that do not contain LRRC8E. | ||||||
Phloretin | 60-82-2 | sc-3548 sc-3548A | 200 mg 1 g | $64.00 $255.00 | 13 | |
Phloretin is a phenolic compound that has been shown to inhibit a variety of anion channels. By inhibiting certain populations of anion channels, phloretin could lead to a compensatory activation of LRRC8E-containing VRACs as the cell attempts to maintain ion homeostasis. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid is a member of the fenamate group of nonsteroidal anti-inflammatory drugs and has been shown to interact with various ion channels. It may activate LRRC8E-containing channels by modulating the membrane environment or through direct interaction with the channel, altering its gating properties. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, a selective estrogen receptor modulator, has been shown to activate chloride channels indirectly. It may activate LRRC8E by altering the cellular context in which VRACs operate, such as changing the phosphorylation state of channel subunits or interacting with regulatory proteins. | ||||||
Benzbromarone | 3562-84-3 | sc-233934 sc-233934A | 1 g 5 g | $53.00 $223.00 | ||
Benzbromarone is a uricosuric agent that acts on anion transport in the kidneys. It may activate LRRC8E-containing VRACs in a similar manner, possibly by interacting directly with the channel or altering cellular ion concentrations that favor VRAC activation. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $32.00 | 3 | |
Niflumic acid, another fenamate NSAID, has been shown to interact with various chloride channels. It could activate LRRC8E-containing VRACs through mechanisms similar to flufenamic acid, such as direct interaction or modulation of the lipid environment. | ||||||
Clofibric acid | 882-09-7 | sc-203000 sc-203000A | 10 g 50 g | $24.00 $40.00 | 1 | |
Clofibric acid, a fibrate drug used to regulate lipid levels, has been reported to interact with chloride channels. Its activation of LRRC8E could be hypothesized as being due to its interaction with lipid membranes or regulatory proteins that control VRAC activity. | ||||||
Taurine | 107-35-7 | sc-202354 sc-202354A | 25 g 500 g | $48.00 $102.00 | 1 | |
Taurine is an amino acid that has been shown to modulate cell volume and osmotic balance. It could potentially activate LRRC8E through osmoregulatory mechanisms that necessitate VRAC activity to counteract changes in cell volume. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
Arachidonic acid is a fatty acid that can modulate the activity of various ion channels. Its potential activation of LRRC8E may stem from the modulation of the membrane environment or by serving as a signaling molecule that activates pathways leading to the opening of VRACs | ||||||